CANF
Price
$1.91
Change
-$0.04 (-2.05%)
Updated
Apr 26, 6:59 PM EST
ORMP
Price
$2.46
Change
+$0.16 (+6.96%)
Updated
Apr 26, 6:59 PM EST
32 days until earnings call
Ad is loading...

Compare predictions CANF vs ORMP

Header iconCANF vs ORMP Comparison
Open Charts CANF vs ORMPBanner chart's image
Can-Fite BioPharma
Price$1.91
Change-$0.04 (-2.05%)
Volume$1.4K
CapitalizationN/A
Oramed Pharmaceuticals
Price$2.46
Change+$0.16 (+6.96%)
Volume$58.45K
CapitalizationN/A
View a ticker or compare two or three
CANF vs ORMP Comparison Chart

Loading...

CANFDaily Signal changed days agoGain/Loss if shorted
 
Show more...
ORMPDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
CANF vs. ORMP commentary
Apr 27, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CANF is a Sell and ORMP is a StrongBuy.

COMPARISON
Comparison
Apr 27, 2024
Stock price -- (CANF: $1.98 vs. ORMP: $2.46)
Brand notoriety: CANF and ORMP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CANF: 47% vs. ORMP: 58%
Market capitalization -- CANF: $10.3M vs. ORMP: $99.68M
CANF [@Biotechnology] is valued at $10.3M. ORMP’s [@Biotechnology] market capitalization is $99.68M. The market cap for tickers in the [@Biotechnology] industry ranges from $556.22B to $0. The average market capitalization across the [@Biotechnology] industry is $2.54B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CANF’s FA Score shows that 1 FA rating(s) are green whileORMP’s FA Score has 0 green FA rating(s).

  • CANF’s FA Score: 1 green, 4 red.
  • ORMP’s FA Score: 0 green, 5 red.
According to our system of comparison, CANF is a better buy in the long-term than ORMP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CANF’s TA Score shows that 5 TA indicator(s) are bullish while ORMP’s TA Score has 5 bullish TA indicator(s).

  • CANF’s TA Score: 5 bullish, 5 bearish.
  • ORMP’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both CANF and ORMP are a good buy in the short-term.

Price Growth

CANF (@Biotechnology) experienced а 0.00% price change this week, while ORMP (@Biotechnology) price change was +8.37% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.69%. For the same industry, the average monthly price growth was -8.16%, and the average quarterly price growth was +1262.42%.

Reported Earning Dates

CANF is expected to report earnings on Jun 01, 2023.

ORMP is expected to report earnings on Aug 07, 2024.

Industries' Descriptions

@Biotechnology (+1.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for CANF with price predictions.
OPEN
A.I.dvisor published
a Summary for ORMP with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
ORMP($99.7M) has a higher market cap than CANF($10.3M). ORMP YTD gains are higher at: 6.494 vs. CANF (-10.000).
CANFORMPCANF / ORMP
Capitalization10.3M99.7M10%
EBITDAN/AN/A-
Gain YTD-10.0006.494-154%
P/E RatioN/A17.57-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
CANF vs ORMP: Fundamental Ratings
CANF
ORMP
OUTLOOK RATING
1..100
8059
VALUATION
overvalued / fair valued / undervalued
1..100
29
Undervalued
63
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9885
PRICE GROWTH RATING
1..100
5952
P/E GROWTH RATING
1..100
10072
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CANF's Valuation (29) in the Biotechnology industry is somewhat better than the same rating for ORMP (63) in the Pharmaceuticals Other industry. This means that CANF’s stock grew somewhat faster than ORMP’s over the last 12 months.

CANF's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ORMP (100) in the Pharmaceuticals Other industry. This means that CANF’s stock grew similarly to ORMP’s over the last 12 months.

ORMP's SMR Rating (85) in the Pharmaceuticals Other industry is in the same range as CANF (98) in the Biotechnology industry. This means that ORMP’s stock grew similarly to CANF’s over the last 12 months.

ORMP's Price Growth Rating (52) in the Pharmaceuticals Other industry is in the same range as CANF (59) in the Biotechnology industry. This means that ORMP’s stock grew similarly to CANF’s over the last 12 months.

ORMP's P/E Growth Rating (72) in the Pharmaceuticals Other industry is in the same range as CANF (100) in the Biotechnology industry. This means that ORMP’s stock grew similarly to CANF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CANFORMP
RSI
ODDS (%)
Bullish Trend 1 day ago
72%
Bullish Trend 1 day ago
66%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
71%
Momentum
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
84%
MACD
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 1 day ago
85%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
85%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 9 days ago
80%
Bullish Trend 4 days ago
84%
Declines
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 10 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
70%
Bullish Trend 1 day ago
79%
Aroon
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
88%
View a ticker or compare two or three
Ad is loading...
CANFDaily Signal changed days agoGain/Loss if shorted
 
Show more...
ORMPDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TMDIF0.04N/A
+7.84%
Titan Medical
MSADY17.950.26
+1.47%
MS&AD Insurance Group Holdings
ORKLY6.720.03
+0.40%
Orkla AS
DSVSF0.68N/A
+0.22%
Discovery Silver Corp
AXAHY34.020.06
+0.19%
AXA SA

CANF and

Correlation & Price change

A.I.dvisor indicates that over the last year, CANF has been loosely correlated with ALDX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CANF jumps, then ALDX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CANF
1D Price
Change %
CANF100%
+3.13%
ALDX - CANF
46%
Loosely correlated
-0.25%
TPST - CANF
27%
Poorly correlated
+1.72%
BCEL - CANF
26%
Poorly correlated
-6.43%
ORMP - CANF
26%
Poorly correlated
+6.96%
ARWR - CANF
25%
Poorly correlated
+1.14%
More

ORMP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ORMP has been loosely correlated with KRYS. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ORMP jumps, then KRYS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORMP
1D Price
Change %
ORMP100%
+6.96%
KRYS - ORMP
48%
Loosely correlated
+0.77%
VXRT - ORMP
48%
Loosely correlated
+7.79%
MORF - ORMP
46%
Loosely correlated
+0.32%
ARCT - ORMP
45%
Loosely correlated
+1.45%
CRBU - ORMP
45%
Loosely correlated
-1.33%
More